US-based medical device maker TVA Medical completed a $15m series C round led by Baxter Ventures, the corporate venturing subsidiary of pharmaceutical company Baxter, yesterday.
Medical devices manufacturer Boston Scientific also took part in the round, investing alongside Santé Ventures, S3 Ventures, TriStar Technology Ventures and additional, unnamed investors.
Founded in 2008, TVA is working on minimally invasive treatments for end-stage renal disease. The company’s lead product, Everlinq EndoAVF, has received regulatory approval in the European Union for patients with chronic kidney disease who require dialysis.
The funding will support further clinical studies and research for Everlinq and the introduction of the product to the market.
TVA previously raised $9.5m in a 2013 series B round led by S3 that also featured Santé, which had already provided $2.6m of series A capital for the company in 2010, and TriStar.